The U.S. Food and Drug Administration (FDA) approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce ...
Pfizer has announced the approval of HYMPAVZI by the US Food and Drug Administration (FDA) for patients with haemophilia A ...
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved HYMPAVZIâ„¢ ...
The FDA approved Pfizer’s Hympavzi, which can be an alternative to intravenous infusions often administered multiple times a ...
The monoclonal antibody is the first non-factor, once-weekly treatment approved in the United States for hemophilia B.
The FDA approved Pfizer’s Hympavzi (marstacimab-hncq) to prevent or reduce the frequency of bleeding episodes in patients age ...
Marstacimab is a human monoclonal immunoglobulin G type 1 antibody that enhances coagulation by targeting the Kunitz 2 domain of tissue factor pathway inhibitor.
The FDA granted the approval of Hympavzi to Pfizer Inc.
Pfizer announced on Friday that the U.S. Food and Drug Administration has granted approval for its once-weekly injection ...
The drug, Hympavzi, is given under the skin through an auto-injector pen to prevent or reduce bleeding episodes in hemophilia ...